Payment overview · 2025
General Payments
$650.31
31 reported records · 14 companies
Healthcare provider profile · identity verified
Susan E. Graves, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLINE, MO · NPI 1861581084
Verified facts
What the public records show
CMS Open Payments records show Susan E. Graves, M.D. received $650.31 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Mounjaro, Ozempic, Rybelsus, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.02 | 35.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.75 | 10.1% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $55.13 | 8.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.69 | 7.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.99 | 5.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $37.64 | 5.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.41 | 5.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.84 | 4.4% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.85 | 4.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.03 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.30 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.62 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.52 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.52 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $650.31 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $167.09 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.93 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $55.13 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.80 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.80 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.99 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.84 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
133 | 102 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
96 | 96 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 619 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 124 |
| Omeprazole | Omeprazole | 399 | 97 |
| Lisinopril | Lisinopril | 390 | 118 |
| Losartan Potassium | Losartan Potassium | 348 | 102 |
| Gabapentin | Gabapentin | 298 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 256 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 252 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 67 |
| Montelukast Sodium | Montelukast Sodium | 214 | 46 |
| Carvedilol | Carvedilol | 203 | 58 |
| Potassium Chloride | Potassium Chloride | 199 | 63 |
| Simvastatin | Simvastatin | 197 | 50 |
| Trazodone Hcl | Trazodone Hcl | 185 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 45 |
| Metformin Hcl Er | Metformin Hcl | 142 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 31 |
| Alprazolam | Alprazolam | 141 | 23 |
| Sertraline Hcl | Sertraline Hcl | 140 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 42 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 133 | 102 |
| Tramadol Hcl | Tramadol Hcl | 127 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 22 |
| Eliquis | Apixaban | 119 | 21 |
| Metformin Hcl | Metformin Hcl | 117 | 36 |
| Furosemide | Furosemide | 115 | 35 |
| Allopurinol | Allopurinol | 114 | 30 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 108 | 108 |
| Pregabalin | Pregabalin | 103 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 32 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 96 | 96 |
| Bupropion Xl | Bupropion Hcl | 93 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 26 |
| Famotidine | Famotidine | 86 | 27 |
| Meloxicam | Meloxicam | 83 | 18 |
| Spironolactone | Spironolactone | 83 | 22 |
| Jardiance | Empagliflozin | 73 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 14 |
| Farxiga | Dapagliflozin Propanediol | 68 | 16 |
| Ozempic | Semaglutide | 63 | 18 |
| Baclofen | Baclofen | 61 | suppressed |
| Lovastatin | Lovastatin | 56 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 15 |
| Alendronate Sodium | Alendronate Sodium | 52 | 18 |
| Celecoxib | Celecoxib | 52 | 14 |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Estradiol | Estradiol | 38 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Diazepam | Diazepam | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nystatin | Nystatin | 18 | 13 |
| Prednisone | Prednisone | 18 | 14 |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 13 |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Tdvax | Tetanus, Diphtheria Tox,adult | 14 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $650.31 · 31 records | Novo Nordisk Inc | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FREESTYLE LIBRE, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, Wegovy, YUPELRI, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error